First licensed treatment for ultra-rare immune disorder recommended
Leniolisib is the first ever treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) licensed for use in the NHS in England.
News, blogs and podcasts
Latest articles
First daily pill for endometriosis approved for NHS use
Today we've recommended the first long-term daily pill to treat endometriosis that could transform how this painful condition is managed.
Second consultation launched on NHS funding for Alzheimer's treatments
Cost and evidence gaps remain barriers to approving funding in the NHS for donanemab and lecanemab.
New drug approved for inherited clotting disorder, offering simpler dosing and enhanced quality of life.
NICE publishes final draft guidance recommending efanesoctocog alfa as an option for treating and preventing bleeding in people aged 2 and over with severe haemophilia A.
Latest in-depth
NICE in 2024: Highlights from our 25th year
An end of year summary from our chief executive, Dr Sam Roberts.
What is our severity modifier?
A guide to the severity modifier and how it is leading to more positive recommendations overall from NICE.
Latest blogs
Harnessing expertise to improve patient access to innovative health technologies
Introducing the Medicines and Medical Devices Access Initiative (MMD): a new collaboration that aims to improve patient access to safe, clinically and cost-effective healthcare products.
NICE’s prioritisation process explained – what healthtech developers need to know
Understand why we're prioritising key topic areas for evaluation and what it means for innovators
Latest podcasts
NICE's positive recommendations for lung cancer treatments
Learn more about the proposed changes to our routing criteria for highly specialised technologies
